Secura Bio, Inc’s Rights Acquisition Of Copiktra®

Paul Hastings LLP advised Secura Bio, Inc., while Ropes & Gray represented Verastem Oncology on the deal.

Secura Bio, Inc., an integrated biopharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, acquired the global rights to Copiktra® (duvelisib) from Verastem, Inc.

The transaction involved a complex structure of regulatory milestones, royalty payments and revenue milestones across multiple jurisdictions, including the United States, European Union, Russia, Japan and China. Secura Bio will make an up-front payment of $70 million upon the closing of the transaction and the total deal value can exceed $310 million if certain regulatory and sales-based milestones are successfully met by Secura Bio and Copiktra’s other rest-of-world partners.

Copiktra, an oral inhibitor of phosphoinositide 3-kinase (PI3K), is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies.

Secura Bio will aggressively support the development of Copiktra in the treatment of T-cell lymphomas for which the PI3K inhibition-based mode of action is highly relevant, and explore new therapeutic opportunities for which the combination of PI3K and HDAC inhibitors may provide superior clinical outcomes.

The transaction will be partially financed with $70 million debt financing led by Athyrium Capital Management, LP.  Paul Hastings also represented Secura Bio in the acquisition financing.

Paul Hastings team acting for Secura Bio was led by M&A partner Deyan Spiridonov (Picture) and included Finance partner Katherine Bell, Intellectual Property partner Todd Schwartz and associates Ryan Enchelmayer, Tyler Dodge, Philip Cernera, Riley Millender, Nahal Bahri and Annalise Olson.

The Ropes & Gray team advising Verastem was led by capital markets partner Marko Zatylny and associates Stephanie Lapidus (both of Boston) and Asiya Ubaid (New York) and included tax partner David Saltzman (Boston), life sciences regulatory & compliance partner Albert Cacozza(Washington, D.C.), employment & benefits partners William Jewett and Megan Bisk (both of Boston), IP transactions partner Mark Bellomy (Boston), litigation & enforcement partners Jonathan Klarfeld (Washington, D.C.) and Adam Harris (New York).

Involved fees earner: Nahal Bahri – Paul Hastings; Katherine Bell – Paul Hastings; Tyler Dodge – Paul Hastings; Ryan Enchelmayer – Paul Hastings; Riley Millender – Paul Hastings; Annalise Olson – Paul Hastings; Todd Schwartz – Paul Hastings; Deyan Spiridonov – Paul Hastings; Mark Bellomy – Ropes & Gray; Megan Bisk – Ropes & Gray; Albert Cacozza – Ropes & Gray; Adam Harris – Ropes & Gray; William Jewett – Ropes & Gray; Jonathan Klarfeld – Ropes & Gray; Stephanie Lapidus – Ropes & Gray; David Saltzman – Ropes & Gray; Asiya Ubaid – Ropes & Gray; Marko Zatylny – Ropes & Gray;

Law Firms: Paul Hastings; Ropes & Gray;

Clients: Secura Bio, Inc.; Verastem, Inc (Verastem Oncology);

Author: Ambrogio Visconti